Cargando…

Patient-reported outcomes in breast cancer FDA drug labels and review documents

BACKGROUND: Patient-reported outcomes (PROs) can provide valuable information about drug benefit-risk tradeoffs from the patient perspective and are particularly important to patients with breast cancer due to its symptoms and adverse events from breast cancer treatments. The United States Food and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Kyungwan, Majercak, Kayleigh R., Villalonga-Olives, Ester, Perfetto, Eleanor M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060367/ https://www.ncbi.nlm.nih.gov/pubmed/33881661 http://dx.doi.org/10.1186/s41687-021-00308-y

Ejemplares similares

Capturing the patient experience in systemic lupus erythematosus: Are widely used measures fit-for-purpose and adherent to FDA PRO guidance recommendations?
por: Majercak, Kayleigh R., et al.
Publicado: (2022)

Social capital and cost-related medication nonadherence (CRN): A retrospective longitudinal cohort study using the Health and Retirement Study data, 2006–2016
por: Majercak, Kayleigh R., et al.
Publicado: (2020)

Longitudinal impact of volunteering on the cognitive functioning of older adults: A secondary analysis from the US Health and Retirement Study
por: Villalonga-Olives, Ester, et al.
Publicado: (2023)

Correction/Clarification about FDA Review Documents
por: Turner, Erick
Publicado: (2005)

Mining FDA drug labels for medical conditions
por: Li, Qi, et al.
Publicado: (2013)

Social Capital during the First Wave of the COVID-19 Outbreak: The Case of the Island of Menorca
por: Villalonga-Olives, Ester, et al.
Publicado: (2021)

Investigating drug repositioning opportunities in FDA drug labels through topic modeling
por: Bisgin, Halil, et al.
Publicado: (2012)

Assessing Readability of FDA-Required Labeling for Breast Implants
por: Powell, Lauren, et al.
Publicado: (2023)

SAT-LB005 Association of Serum Estrogens and Estrogen Metabolites with Use of Non-Steroidal Anti-Inflammatory Drugs in Postmenopausal Women
por: Fuhrman, Barbara, et al.
Publicado: (2019)

Emergent Social Capital during the Coronavirus Pandemic in the United States in Hispanics/Latinos
por: Contreras, Jennifer, et al.
Publicado: (2023)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Longitudinal changes in health related quality of life in children with migrant backgrounds
por: Villalonga-Olives, Ester, et al.
Publicado: (2017)

Mining FDA drug labels using an unsupervised learning technique - topic modeling
por: Bisgin, Halil, et al.
Publicado: (2011)

Children’s Mental Health: Discrepancy between Child Self-Reporting and Parental Reporting
por: Caqueo-Urízar, Alejandra, et al.
Publicado: (2022)

Development and validation of a questionnaire to measure family social capital
por: Carrillo-Álvarez, Elena, et al.
Publicado: (2019)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022)

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
por: Park, Siyeon, et al.
Publicado: (2019)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
por: Hung, Anna, et al.
Publicado: (2016)

Racial and ethnic differences in the association of social cohesion and social capital with HIV testing
por: Ransome, Yusuf, et al.
Publicado: (2022)

Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021)

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018)

FDA review times for new drugs in ophthalmology
por: Carpenter, Michelle A., et al.
Publicado: (2020)

The development of a bridging social capital questionnaire for use in population health research
por: Villalonga-Olives, E., et al.
Publicado: (2016)

Health related quality of life of immigrant children: towards a new pattern in Germany?
por: Villalonga-Olives, Ester, et al.
Publicado: (2014)

Understanding the new FDA pregnancy and lactation labeling rules()
por: Blattner, Collin M., et al.
Publicado: (2016)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Rasch model of the bridging social capital questionnaire
por: Villalonga-Olives, E., et al.
Publicado: (2021)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
por: Stanek, Eric J., et al.
Publicado: (2013)

Effects of Resilience and Acculturation Stress on Integration and Social Competence of Migrant Children and Adolescents in Northern Chile
por: Caqueo-Urízar, Alejandra, et al.
Publicado: (2021)

Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
por: Rodriguez, Ryan, et al.
Publicado: (2021)

Pediatric Health-Related Quality of Life: A Structural Equation Modeling Approach
por: Villalonga-Olives, Ester, et al.
Publicado: (2014)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Reply to “Consensus document on tracheotomy in patients with COVID-19”()
por: Martín Delgado, M.C., et al.
Publicado: (2021)

FDA relations during drug development
por: Mitchel, Jules T.
Publicado: (2000)

FDA and Its Role in Drug Development
por: Pazdur, Richard
Publicado: (2021)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2esfhjm6rvo0nbg269e7s017ie